ARS Pharmaceuticals, Inc.

corporate_fare Company Profile

ARS Pharmaceuticals, Inc.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed SPRY - Latest Insights

Filing Type

Date Range

SPRY

Apr 15, 2026, 6:05 AM EDT

Source: GlobeNewswire

Importance Score:

8

Canada Approves ARS Pharma's Neffy Epinephrine Nasal Spray, Triggering Milestones

Sentiment: Positive

View Wiseek Article

SPRY

Mar 27, 2026, 8:00 AM EDT

Source: GlobeNewswire

Importance Score:

8

FDA Removes Age Restriction for neffy® 1 mg, Expanding Pediatric Market for ARS Pharma

Sentiment: Positive

View Wiseek Article

SPRY

Mar 16, 2026, 8:53 AM EDT

Source: FinanceWire

Importance Score:

8

New Nasal Epinephrine Powder Outperforms ARS Pharma's Neffy in Phase 2 Speed Data

Sentiment: Negative

View Wiseek Article

SPRY

Mar 09, 2026, 6:07 AM EDT

Filing Type: 10-K

Importance Score:

8

ARS Pharma Reports Significant 2025 Net Loss Amid Neffy Launch, Faces Generic Threat & FDA Scrutiny

Sentiment: Negative

View Wiseek Article

SPRY

Mar 09, 2026, 6:02 AM EDT

Source: Dow Jones Newswires

Importance Score:

7

ARS Pharmaceuticals Reports $1.74/Share Loss for Fiscal 2025

Sentiment: Negative

View Wiseek Article